Wang Zeng, Cai Xin-Jun, Chen Ling Ya, Cheng Bin, Shi Liang, Lei Lei, Ye Liu-Qing, Lin Neng-Ming
Department of Pharmacy, Zhejiang Cancer Hospital; Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, People's Republic of China.
Department of Pharmacy, Integrated Chinese and Western Medicine Hospital of Zhejiang Province, Hangzhou 310003, Zhejiang, People's Republic of China.
J Cancer Res Ther. 2018 Sep;14(Supplement):S656-S660. doi: 10.4103/0973-1482.187338.
To investigate the prevalence and characteristics of gemcitabine-based chemotherapy-induced thrombocytopenia in Chinese patients with nonsmall cell lung cancer (NSCLC).
Medical records of 197 patients with histologically proven NSCLC received gemcitabine-based chemotherapy from June 2011 to June 2013 in our hospital were collected. The relative risk factors were identified and evaluated by univariate and multivariate analyses.
The incidence of gemcitabine-based chemotherapy-induced thrombocytopenia in these NSCLC patients was 85.8%. Between thrombocytopenia and nonthrombocytopenia patients, in patients with thrombocytopenia and thrombocytopenia, we found Stage III/IV patients got more probabilities for thrombocytopenia (P < 0.01). In addition, patients who received gemcitabine and cisplatin (GP) regimen resulted in more thrombocytopenia than gemcitabine and carboplatin (GC) and other regimens (P < 0.001). In addition, majority of the thrombocytopenia patients presented thrombocytopenia in their first cycle (P < 0.001). Whereas, other potential risk factors such as age, gender, performance status value, diabetes mellitus or not, and other underlying disease (hypertension and hepatopathy) were not showed such significance in this study. Further, the multivariate analysis revealed that stage (odds ratio [OR] 7.113, P < 0.01) and chemotherapy cycles (OR 0.543, P < 0.01) were also statistically significant independent risk factors for gemcitabine-based chemotherapy-induced thrombocytopenia.
This study shows that thrombocytopenia is common in Chinese NSCLC patients receiving gemcitabine-based regimens. Chemotherapy cycles and stage might be the important factors influencing the occurrence of gemcitabine-based regimens-induced thrombocytopenia.
探讨中国非小细胞肺癌（NSCLC）患者中吉西他滨为主的化疗所致血小板减少症的发生率及特点。
收集我院2011年6月至2013年6月间197例经组织学证实的NSCLC患者接受吉西他滨为主化疗的病历资料。通过单因素和多因素分析确定并评估相关危险因素。
这些NSCLC患者中吉西他滨为主的化疗所致血小板减少症的发生率为85.8%。在血小板减少症患者与非血小板减少症患者之间，在血小板减少症患者中，我们发现Ⅲ/Ⅳ期患者发生血小板减少症的概率更高（P<0.01）。此外，接受吉西他滨联合顺铂（GP）方案的患者比接受吉西他滨联合卡铂（GC）及其他方案的患者发生血小板减少症的情况更多（P<0.001）。另外，大多数血小板减少症患者在其第一个周期出现血小板减少症（P<0.001）。然而，年龄、性别、体能状态评分、是否患有糖尿病以及其他基础疾病（高血压和肝病）等其他潜在危险因素在本研究中未显示出此类显著性。进一步的多因素分析显示，分期（比值比[OR]7.113，P<0.01）和化疗周期（OR 0.543，P<0.01）也是吉西他滨为主的化疗所致血小板减少症的具有统计学意义的独立危险因素。
本研究表明，接受吉西他滨为主方案治疗的中国NSCLC患者中血小板减少症很常见。化疗周期和分期可能是影响吉西他滨为主方案所致血小板减少症发生的重要因素。
